Keytruda

News

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.

News

NICE backs NHS funding for MSD's Keytruda combination in lun...

NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung cancer patients.

News

Ex-Merck & Co scientist accused of stealing trade secrets co...

A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US auth

News

Genprex cancer gene therapy paired with AZ, Merck lung cance...

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda - both leading their respective drug classes in the

News

FDA sets Feb decision date for Libtayo lung cancer challenge...

The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche

News

NICE changes stance on Keytruda for first-line head and neck...

As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and n

Merck gets a leg-up for Keytruda in first-line kidney cancer

NICE backs NHS funding for MSD's Keytruda combination in lun...

Ex-Merck & Co scientist accused of stealing trade secrets co...

Genprex cancer gene therapy paired with AZ, Merck lung cance...

FDA sets Feb decision date for Libtayo lung cancer challenge...

NICE changes stance on Keytruda for first-line head and neck...

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Keytruda

Editor's Picks